ClinicalTrials.gg
RecruitingNCT04706390COVID19vac-1Updated Apr 19, 2024

Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination

An observational study in Covid19, sponsored by University of Bergen. Recruiting at 1 site in Norway. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by University of Bergen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in COVID-19 with a site in Norway — 3 open to participants now, 7 under way, 1 of them phase 3. COVID-19 · Norway.

Planned enrollment
7th of 23
2,500 · median 860
Started
2021
with 9 others
Observational
23 of 47
1 open now
Registered
24th of 47
by date

Among the 47 studies in COVID-19 with a site in Norway, this one is the 7th largest by planned enrollment of the 23 observational ones that give a count, is one of 10 that started in 2021, is one of 23 observational ones, and was the 24th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 47 studies in COVID-19 with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in COVID-19 with a site in Norway, or all of them as a file.
02

Study summary

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has been intensified by no population-based immunity to the severe acute respiratory disease coronavirus 2 (SARS-CoV2) and initially lack of effective treatments or vaccines available to mitigate the pandemic. Currently, two COVID-19 vaccines are available for vaccination in Europe through conditional marketing authorisation granted by the European Medicines Agency and further vaccine will be licensed. These vaccines have shown good vaccine efficacy in phase 3 vaccine trials. We will recruit subjects who will be prioritised for vaccination with the primary aim of comparing the immune responses after COVID-19 vaccination and natural SARS-CoV-2 infection. In Western Norway we have recruited cohorts of health care workers and patients infected with SARS-CoV-2 and will extend to COVID-19 vaccinees. Demographic, clinical data and repeated blood samples will be collected to evaluate the complications and kinetics, duration and breadth of the immune responses comparing natural infection to vaccination.

Read the detailed description

The primary aim of this study is

  • To compare immune responses after natural SARS-CoV-2 infection and COVID-19 vaccination The secondary aims are
  • To compare the duration and breadth of antibody responses between natural infection and vaccination.
  • To investigate the duration and breadth of B and T cellular responses between natural infection and vaccination.
  • To evaluate the short and long term complications after natural infection and vaccination.
  • To find out if previous infection skews the immune response after vaccination.
  • To study reinfection after natural infection and vaccination.
03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • Covid19
  • Vaccine
  • SARS-CoV-2 antibody
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Comparator group: patients with natural SARS-CoV-2 infection Vaccine groups: Health care workers and high-risk population groups.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects prioritized by national vaccination program

Exclusion criteria

Exclusion Criteria:

  • Children
  • unable or unwilling to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Health care workers

    500-1000 health care workers prioritized for early vaccination

    Biological: covid-19 vaccine

  • prioritized patient populations

    2000 individuals in patient populations prioritized for vaccinations

    Biological: covid-19 vaccine

Interventions

  • Biologicalcovid-19 vaccine

    vaccination

06

What researchers measure

Primary outcomes

  1. immune responses

    spike antibody response to SARS-CoV-2

    Time frame: 2 months to 3 years

Secondary outcomes

  1. Duration and breadth of B- cell responses

    compare serological and memory B cells after vaccination to natural infection

    Time frame: 2 months to 3 years

  2. Duration and breadth of T cell responses

    compare T cell responses after vaccination to natural infection

    Time frame: 2 months to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cox RJ, Brokstad KA, Krammer F, Langeland N; Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Lancet Infect Dis. 2021 Feb;21(2):168. doi: 10.1016/S1473-3099(20)30466-7. Epub 2020 Jun 15. No abstract available. Erratum In: Lancet Infect Dis. 2020 Sep;20(9):e215. doi: 10.1016/S1473-3099(20)30554-5. PubMed 32553187 ↗
  • Trieu MC, Bansal A, Madsen A, Zhou F, Saevik M, Vahokoski J, Brokstad KA, Krammer F, Tondel C, Mohn KGI, Blomberg B, Langeland N, Cox RJ; Bergen COVID-19 Research Group. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. J Infect Dis. 2021 Feb 24;223(4):589-599. doi: 10.1093/infdis/jiaa737. PubMed 33247924 ↗

Individual participant data

Plan to share: Undecided — To be developed

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2024, 47 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 47 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 12, 2021
StartActual
Jan 12, 2021
Primary completionEst.
Dec 12, 2024
CompletionEst.
Dec 12, 2030
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04706390
Responsible party
Rebecca Cox (Professor, University of Bergen) — Principal investigator
First posted
Jan 12, 2021
Start date
Jan 12, 2021
Primary completion
Dec 12, 2024 (estimated)
Completion
Dec 12, 2030 (estimated)
Last update
Apr 19, 2024

Study contacts

Rebecca J Cox, PhD
Contact
rebecca.cox@uib.no
+4745242974
Nina Langeland, MD
Contact
nina.langeland@uib.no
+4741616450
Rebecca J Cox, PhD
principal investigator · University of Bergen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion